Tirzepatide Shows Promise in Diabetes Prevention and Weight Loss
A study published in the New England Medical Journal reveals that tirzepatide, the active ingredient in Eli Lilly's Mounjaro, significantly reduces the risk of developing diabetes by 94% in high-risk individuals. Conducted over three years with over 2500 pre-diabetic participants, the trial showed that only 1.3% of those taking tirzepatide developed diabetes compared to 13.3% in the placebo group. The drug, which mimics the body's feeling of fullness, also led to substantial weight loss and maintained blood sugar control, suggesting long-term protective benefits against diabetes.
